CTI BioPharma (NASDAQ: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of ... novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. Pacritinib is also being investigated in acute graft versus host disease (GvHD) in an ongoing investigator-sponsored Phase 1/2 study. We are headquartered in Seattle, Washington. read more